Drug Trial Radar · NCT07262268
A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5
Planned (sponsor's estimate)
Start
Jan 15, 2026
Primary completion
Nov 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Biohaven Therapeutics Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the potential benefits of BHV-7000 in reducing chronic pain in participants with IEM with a previously demonstrated gain of function mutation in the SCN9A gene.
Conditions
- Familial Erythromelalgia
Interventions
BHV-7000Drug
Participants will take blinded investigational product (IP) orally once daily
PlaceboDrug
Matching placebo taken orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean of the daily average maximum pain intensity scores collected every 2 hours.Time frame: The last 3 weeks of each 4-week crossover treatment period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site-001
New Haven, Connecticut
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.